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The composition of human gut microbiota and their relationship with the host and, conse-
quently, with human health and disease, presents several challenges to microbiologists.
Originally dominated by culture-dependent methods for exploring this ecosystem, the
advent of molecular tools has revolutionized our ability to investigate these relationships.
However, many biases that have led to contradictory results have been identified. Microbial
culturomics, a recent concept based on a use of several culture conditions with identifica-
tion by MALDI-TOF followed by the genome sequencing of the new species cultured had
allowed a complementarity with metagenomics. Culturomics allowed to isolate 31 new
bacterial species, the largest human virus, the largest bacteria, and the largest Archaea
from human. Moreover, some members of this ecosystem, such as Eukaryotes, giant
viruses, Archaea, and Planctomycetes, have been neglected by the majority of studies.
In addition, numerous factors, such as age, geographic provenance, dietary habits, antibi-
otics, or probiotics, can influence the composition of the microbiota. Finally, in addition
to the countless biases associated with the study techniques, a considerable limitation to
the interpretation of studies of human gut microbiota is associated with funding sources
and transparency disclosures. In the future, studies independent of food industry funding
and using complementary methods from a broad range of both culture-based and mole-
cular tools will increase our knowledge of the repertoire of this complex ecosystem and
host-microbiota mutualism.
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INTRODUCTION
The exhaustive description of human microbiota and their rela-
tionship with health and disease are major challenges in the
twenty-first century (Turnbaugh et al., 2007). To assess the impor-
tance of this challenge, we used the ISI Web of Knowledge to
demonstrate the dramatically renewed interest of scientists in this
subject. To extend the chart presented by Sekirov et al. (2010);
Marchesi (2011), which lists the number of publications per year
involving human gut microbiota, we found that in 2011, there
were more than 4 times as many citations referencing human
gut microbiota than in 2005 (Figure 1A), when Eckburg et al.
(2005) published the seminal large-scale gut metagenomics study.
In addition, in 2011, there were approximately as many published
items investigating human gut microbiota than during the 10 years
between 1993 and 2002 (Figure 1B).
The human gut microbiota is composed of approximately
1011–12 microorganisms per gram of content, including diverse
populations of bacteria, mainly anaerobes (95% of the total),
which is 10 times higher than the total number of human cells (Ley
et al., 2006a). In the study of human gut microbiota, two major
technological periods can be distinguished: schematic microscopic
observation and culture-based methods before 1995 followed by
the advent of culture-independent methods. This technology-
driven progress led to suggest relationships between gut micro-
biota composition and diverse diseases, such as irritable bowel
syndrome (Kassinen et al., 2007), polyposis or colorectal can-
cer (Scanlan et al., 2008), necrotizing enterocolitis (Siggers et al.,
2008), Crohn’s disease (De Hertogh et al., 2006; Manichanh et al.,
2006; Scanlan et al., 2006), and metabolic diseases such as type II
diabetes (Larsen et al., 2010) and obesity (Ley et al., 2006b; Turn-
baugh et al., 2006, 2009; Armougom et al., 2009; Santacruz et al.,
2009).
Based on these early data and to complete the description of the
human gut composition, considerable funds have been granted.
Among the projects pursuing this line of research, the human
microbiome project is an international consortium with the aim of
sequencing 1,000 bacterial genomes and multiplication by metage-
nomic analysis to characterize the complexity of microbial com-
munities at several body sites, including the human gut, to deter-
mine whether there is a core microbiome (Turnbaugh et al., 2007).
Despite these advances in knowledge of gut microbiota compo-
sition, the relationships of the microbiota with their host and,
consequently, with health and disease are still largely unknown,
as reflected in several contradictory results (Sekirov et al., 2010).
Moreover, molecular tools and by extension, experimental mod-
els, often reflect a reductionist approach as opposed to a holistic
approach (Fang and Casadevall, 2011). Nevertheless, an appealing
approach that was recently applied to the study of oral microbiota
will allow us to detect the minor bacterial populations, which are
usually neglected, using dilution to obtain a threshold below 106
bacteria per ml or DNA>1 pg per µl (Biesbroek et al., 2012).
We propose here an inventory of current knowledge regarding
gut microbiota composition, the techniques used for this study
and the relationships with the host. Finally, further research on
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FIGURE 1 | Using the key words “human gut microbiota” or “human
fecal flora” and using the ISI Web of Knowledge database, (A) shows
citations in each year regarding this subject, and (B) shows the
number of published items each year, both between 1993 and 2011.
human gut microbiota is the subject of considerable funding by
the food industry. Consequently, to perform an efficient analysis of
this subject, the design and/or interpretation of the results of each
study can be associated with a conflict of interest. For example, it
has recently been shown that published papers in obesity research
in which the authors were funded by the food industry were more
likely than other papers to contain results or an interpretation that
favored the industry or company that was producing the product
or service that was being studied (Thomas et al., 2008).
REPERTOIRE
CULTURE
Culturing has been the first method used to characterize a bac-
terial ecosystem (Finegold et al., 1974, 1977; Moore and Holde-
man, 1974a). Gut composition was first studied by microscopic
observation and axenic culture. Gram staining has been widely
used by microbiologists to describe stool composition. Using this
technique, gram-positive bacteria accounted for only 2–45% of
the cells observed (Gossling and Slack, 1974). However, a dis-
crepancy arises because culture counts reveal a predominance of
gram-positive bacteria in human feces. Indeed, one of the first
culture studies of human stools showed that anaerobes always
constitute the major component of the culturable flora of chil-
dren and adults (Mata et al., 1969), with a predominance of
gram-positive cells. Moore and Holdeman (1974a), in a study
of 20 individuals, revealed 113 different bacteria, including more
gram-positive bacteria (Bifidobacterium, Eubacterium, Peptostrep-
tococcus, Ruminococcus, Lactobacillus, and Clostridium genera)
than gram-negative bacteria (Bacteroides, Fusobacteria genera;).
Nevertheless, these studies attempted especially to culture anaer-
obic bacterial species whereas some gut bacteria preferentially
grown in microaerophilic conditions.
Among other unique problems associated with bacterial cul-
ture, Moore have also observed a major discordance between the
culture counts and the microscopic counts of species (Moore and
Holdeman, 1974b); these discrepancies have been named by Staley
and Konopka (1985) as the “great plate count anomaly”. Indeed, it
is generally accepted that only 1% of bacteria can be easily grown
in vitro (Vartoukian et al., 2010). Consequently, the major popula-
tion easily isolated from stools is composed of bacteria that grow
quickly in classical high-nutrient growth media, with the usual car-
bon or electron sources at mesophilic temperatures (Hugenholtz,
2002), and this constitutes the most studied bacteria. It is estimated
that approximately 75% of published studies by microbiologists
before the advent of molecular tools focused on only nine bacterial
genera among four phyla (Actinobacteria, Proteobacteria, Firmi-
cutes, Bacteroidetes; Galvez et al., 1998), whereas we know now
that more than 30 different phyla compose the gut microbiota
(Figure 2; Rajilic-Stojanovic et al., 2007). Nevertheless, studies of
these fast-growing and easily cultured bacteria neglect the minor-
ity bacterial populations, including potentially pathogenic bacteria
such as Salmonella typhi.
Finally, considering the main first culture-based studies the
number of bacterial species was estimated at approximately 400–
500 (Mata et al., 1969; Moore and Holdeman, 1974a; Finegold
et al., 1977). In addition to the necessary use of stringent anaerobic
conditions to culture bacteria from human stools, the usual phe-
notypic identification methods are time consuming and expensive
(Seng et al., 2009). Indeed, the exponential technological advances
in molecular tools led microbiologists to progressively abandon
the culture-based approach for studies of the gut microbiota
ecosystem.
METAGENOMICS AND PYROSEQUENCING
As often occurs during scientific progress, technological advances
in microbiology allowed scientists to revisit the knowledge base
(Rajilic-Stojanovic et al., 2007). Since 2000, large-scale 16S rRNA
or metagenomic studies have allowed scientists to dramatically
expand the known diversity of the human gut microbiome, illu-
minating new ways (Eckburg et al., 2005; Andersson et al., 2008).
It is now commonly accepted that approximately 80% of the bac-
teria found by molecular tools in the human gut are uncultured,
and hence can be characterized only by metagenomic studies (Eck-
burg et al., 2005). Whereas the number of species was limited in the
seminal studies using culture-based methods (Finegold et al., 1974;
Moore and Holdeman, 1974b), Turnbaugh et al. (2010) estimated
473 phylotypes using V2 pyrosequencing. There is a significant
discrepancy between bacterial observations with a microscope and
most of the molecular studies, which observe a striking dominance
of gram-positive bacteria (Eckburg et al., 2005; Andersson et al.,
2008; Turnbaugh et al., 2010; Figure 2).
Indeed, these recent methods generate contradictory results
reflecting the biases in every step of the Polymerase Chain Reac-
tion procedure. A dramatic divergence in the proportion of the
different phyla was observed depending of the type of extraction
kit used, notably for the Fusobacteria (2–40%) and Bacteroidetes
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FIGURE 2 | A comparison of Gram staining, electron microscopy, and pyrosequencing to determine the proportion of Gram-positive/Gram-negative
bacteria in the same stool sample (personal data).
(40–60%) phyla (Wu et al., 2010). In addition, the relative abun-
dance of a phylum depends significantly on the 16S hypervariable
region, independent of pyrosequencing chemistry. For example,
the 454 titanium and Illumina next-generation sequencing (NGS)
methods reveal a dominance of the Bacteroidetes phylum using 16S
rDNA v4v5 region primers, whereas Firmicutes was predominant
using v3v4 primers on the same gut microbiota (Claesson et al.,
2010). Using 454 titanium, Ralstonia genera have been detected
only by V4/V5 primers, whereas Bifidobacteria have been detected
only by V3/V4 primers (Turnbaugh et al., 2010). In parallel, Hong
et al. (2009) have described that the rRNA approach misses half of
the bacteria in environmental microbiology.
Although controversial, the higher taxonomic level analyses (as
phylum level) have suggested an association between obesity and
Firmicutes/Bacteroidetes proportion (Ley et al., 2005). The genus-
level analysis has allowed to hypothesize specific enterotypes com-
positions despite controversies (Arumugam et al., 2011). In addi-
tion, Murphy et al. (2012) has recently observed in a study from the
manipulation of the mice gut microbiota in diet-induced obesity
that a better separation of lean and diet-induced obese mice was
observed at the family and genus-level than at the phylum level.
However, the large inter-individual variability leads the analysis of
lower taxonomic-level to complex results because of small number
of samples. Finally, the optimization of primers able to detect gen-
era often misdetected by pyrosequencing, as Bifidobacteria (Sim
et al., 2012), and technology progress in pyrosequencing, will allow
to more quickly analyze longer reads sequenced to study larger
cohort samples in low taxonomic level.
Finally, molecular methods detected bacteria present at concen-
trations greater than approximately 106 and neglected minority
populations. Among these neglected populations are potentially
pathogenic bacteria such as S. typhi, Yersinia enterocolitica, and
Tropheryma whipplei, which may be present in human stools at
concentrations below 105 cfu per ml (Raoult et al., 2010), the cur-
rent threshold of the latest NGS method (Turnbaugh et al., 2010;
Lagier et al., 2012a; Figure 3). The depth is directly correlated with
the number of generated sequences, and no plateau was obtained
in the number of phylotypes observed, although close to 1,000,000
16S rRNA gene amplicons have been sequenced by Turnbaugh
et al. (2010).
VIRUSES
Research in the human gut has been focused on bacterial com-
position (Walker, 2010). Early studies suggested that most DNA
viruses found in the intestine were phages and that most RNA
viruses were plant viruses (Breitbart et al., 2008). Nevertheless,
a recent metagenomic study carried out over 1 year, with three
stools analyzed from each monozygotic adult twin and their
mother, revolutionized virome knowledge (Reyes et al., 2010).
The authors carried out shotgun pyrosequencing to generate over
280 Mb of sequence and, at the same time, a pyrosequencing of
16S rRNA genes to identify the bacterial species. Approximately
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FIGURE 3 |The statistical detection thresholds of metagenomic methods. The statistical detection thresholds of metagenomic methods are correlated with
the number of bacteria in the ecosystem studied by the number of sequences generated.
80% of sequencing reads did not match any known viruses in
the database corresponding to prophages or temperate phages.
These populations were persistent in each individual, with no
significant clustering between co-twins or between twins and
their mothers, contrasting with the bacterial similarity between
twins (Turnbaugh et al., 2009). In addition, Minot et al. (2011)
observed that a change of diet is associated with a change in virome
composition.
CULTUROMICS
There has been a renewed interest in culture methods for these
“non-cultivable” species (Vartoukian et al., 2010). Initially, envi-
ronmental microbiologists were confronted with the fact that the
majority of bacteria do not grow in classical Petri dishes. These
first studies used prolonged incubation and stringent anaerobic
conditions, notably, diffusion chambers (Kaeberlein et al., 2002;
Bollmann et al., 2007), with the aim of simulating the natural
environment of these “uncultivable” microorganisms (Kaeberlein
et al., 2002). This technique enlarged the diversity of the envi-
ronmental microorganisms that were isolated (Epstein, 2009). In
parallel, a recently published study proposed an anaerobic culture
of a single stool sample to complement 16S rRNA sequencing,
using rumen fluid or an extract of fresh stools to mimic the nat-
ural environment of the gut bacteria. Goodman et al. (2011) have
recovered 36 cultured species: four uncultured described species
and 53 unknown isolates with different v2 sequences. However,
these authors used the most probable number (MPC) technique
for creating arrayed species collections that do not detect minority
populations.
In addition to the stringent culture conditions, some of the dif-
ficulties linked to culture include the cost and the amount of time
required for bacterial identification (Seng et al., 2009). These diffi-
culties have recently been overcome by mass spectrometry, which
enables quick and effective identifications in routine bacteriology
(Seng et al., 2009, 2010) and allow the researcher to quickly check
the major population and to concentrate interest on the minor-
ity population. We have recently reported a breakthrough in this
field of research with the microbial culturomics concept (Lagier
et al., 2012a). We applied 212 different culture conditions in two
African stools and a French obese stool samples, including enrich-
ment techniques, Escherichia coli phage cleaning, and innovative
conditions (using rumen fluid, sterile human stools). We analyzed
32,500 colonies by MALDI-TOF, allowed us to culture 340 dif-
ferent bacterial species among seven phyla and 117 genera. This
included 174 species never described in the human gut. More-
over 31 new species were found, including five new genera, as well
two species from rare phyla (Deinococcus-Thermus and Synergis-
tetes). Genome sequencing and description of each new species
is in progress (Kokcha et al., 2012; Lagier et al., 2012b,c; Mishra
et al., 2012a,b,c,d). By comparison, pyrosequencing of 16S rDNA
amplicons from the three stools noted a dramatic discrepancy with
culturomics as only 51 species identified by 16S rDNA amplifi-
cation and sequencing were also found among the 340 cultured
species highlighting the renewed interest for the culture in the gut
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microbiota study. Culturomics allowed us break several “records”
with the largest number of bacteria cultured from a single stool
(219 species), the first bacteria from Deinococcus-Thermus phy-
lum isolated from human, the largest human virus and the largest
bacteria from human (Lagier et al., 2012a).
COMPARISON OF THE TECHNIQUES
There are currently no rational explanations for the typical
observed proportions of gram-positive/negative bacteria, which
are highly divergent microscopically (Turnbaugh et al., 2007) with
culture, (Gossling and Slack, 1974) and the proportions obtained
by sequence detection (Eckburg et al., 2005; Figures 2 and 4). In
2002, Hayashi compared the digestive microbiota of three indi-
viduals by cloning/sequencing and anaerobic culture using the
“plate-in-bottle” method. These researchers isolated between 48
and 65 phylotypes in the cloning of individuals and 48 species,
of which three individuals were potentially three new species
(Hayashi et al., 2002b). In light of the phylogenetic tree described
in this publication, these authors found significant discrepancies
between these two techniques, which were somewhat surprising
given the low number of species and phylotypes identified. Sev-
eral species in culture had no equivalent in cloning. A previous
study compared these same techniques, but the number of species
and phylotypes was even lower (Wilson and Blitchington, 1996).
In this study, of 48 species, 25 were detected only by cloning, nine
were common to both techniques, and 14 were identified only by
culture. In addition, in our microbial culturomics study, by com-
parison with the 340 bacteria cultured, pyrosequencing of 16S
rDNA amplicons from the three stools identified 698 phylotypes
including 282 phylotypes of known bacterial species and 416 phy-
lotypes of uncultured bacteria. We noted a dramatic discrepancy
with culturomics as only 51 species identified by 16S rDNA ampli-
fication and sequencing were also found among the 340 cultured
species. Consequently,microbial culturomics increased by 30% the
microbial repertoire of the human gut studied by pyrosequencing
(Lagier et al., 2012a).
GAPS IN KNOWLEDGE
In addition to the bias previously described, some components of
human gut microbiota have been partially neglected by the current
tools (Figure 5).
EUKARYOTES
Eukaryotes are an important part of the human gut microbiome
and play different beneficial or harmful roles. Some species may be
commensal or mutualistic, whereas others may be opportunistic
or parasitic (Parfrey et al., 2011). The eukaryotic component of the
human gut microbiome remains unexplored because these organ-
isms are of limited interest (Marchesi, 2010). Culture-dependent
techniques and microscopy-based approaches have been mainly
used to explore eukaryotes in the human gut, and identification has
frequently been based on morphological and physiological tech-
niques with numerous biases. Moreover, this approach detects only
a small fraction of microorganisms, including Candida and Sac-
charomyces spp., but the growth requirements for many eukaryotic
species remain unknown.
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FIGURE 5 | A non exhaustive overview of human gut microorganisms among bacterial, Archaea, viral, and Eukaryota domains.
Using culture-independent methods, Scupham et al. (2006)
have identified a large number of fungi, including Ascomycota,
Basidiomycota, Chytridiomycota, and Zygomycota phyla, in stud-
ies of mouse feces. Furthermore, Scanlan and Marchesi (2008),
studying the human distal gut, have shown that the diversity and
abundance of eukaryotes is low relative to those of bacteria. Only
members of the genera Gloeotinia/Paecilomyces and Galactomyces
have been identified as the most abundant. Nevertheless, we have
shown that due to a large variety of primers used, the human gut
contains a broader eukaryotic diversity than predicted (Hamad
et al., 2012). In parallel, applying traditional and modern labo-
ratory techniques (using intergenic spacers for 18S rDNA), the
repertoire of intensive care unit pneumonial microbiota has been
considerably extended, notably regarding fungal microbiota and
plants (Bousbia et al., 2012).
Giant viruses
Giant viruses growing in amoebae have previously been isolated
in the environment, e.g., in the water of cooling towers, in rivers
and lakes, in seawater, in decorative fountains, and in soil (Pag-
nier et al., 2008). Mimivirus DNA has been obtained from the
bronchoalveolar lavage of patients (Raoult et al., 2007; Lysholm
et al., 2012), and a laboratory infection was documented by serol-
ogy (Raoult et al., 2006). In addition, Lysholm et al. (2012), in a
viral microbiome metagenomic study performed in 210 children
and adults with lower respiratory infections, recently identified
Mimivirus. Because the authors used two pools and filtered with
0.22 and 0.45µm pore-size disk filters, they were able to isolate a
giant virus that is frequently missed by large-scale virome metage-
nomics studies that use only 0.22µm filters, making giant virus
detection unlikely (Willner et al., 2009; Reyes et al., 2010).
In our laboratory, in an effort to obtain fastidious bacteria from
an African stool sample by amoeba (Acanthamoeba polyphaga) co-
culture, we obtained a new giant virus strain named Senegal virus
(Lagier et al., 2012a), which we sequenced (Genbank JF909596–
JF909602). These findings indicate that giant viruses may be a
part of the gut microbiota and that virome metagenomic studies
should use different filter sizes. Because the potential pathology
of the giant viruses is currently unknown, it is unreasonable to
neglect them (Boyer et al., 2009).
Archaea
Nottingham and Hungate (1968) isolated a previously uniden-
tified methanogenic Archaea from human feces using a non-
selective medium and a stringent anaerobic atmosphere composed
of 80% H2 and 20% CO2. Miller et al. (1982) isolated Methanobre-
vibacter smithii from human stool specimens from four healthy
adults using anaerobic cultures enriched with the same H2–CO2
anaerobic atmosphere pressurized to two bars. Illustrating the
technical limitations of the fastidious Archaea culture, in our lab-
oratory, we have recently achieved the isolation of the fourth
methanogenic Archaea species in humans and the first cultured
representative of a new order of Archaea (Methanomassiliicoccus
luminyensis) after a 16-month tentative culturing procedure. We
obtained this strain after subtle modifications in the composition
of the culture medium (enzyme co-factors) and adaptation of the
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atmospheric pressure (the culture medium is patented; Dridi et al.,
2012a). In addition, the genome sequencing of this new species
represents the largest genome of a methanogenic euryarchaeota
isolated from humans (Gorlas et al., 2012).
In addition, recent molecular studies indicated that human
Archaea constitute an expanding world (Dridi et al., 2011). Using
16S rDNA sequencing, many studies confirmed the presence of M.
smithii and M. stadtmanae in the human gut, with variable and
low prevalence (Dridi et al., 2009). Nevertheless, in our study, our
new Archaea was detected in stools in 4% of individuals, and its
prevalence increases with age, although its role in human health is
unknown (Dridi et al., 2012b). Regarding the influence of Archaea
on human health, a recent meta-analysis compared the number of
sequences of Methanobrevibacter spp. in stools. Obese individuals
had fewer Methanobrevibacter genera by quantitative polymerase
chain reaction (qPCR) than non-obese subjects (Angelakis et al.,
2012a). Previous studies had reported discordant results concern-
ing the levels of detection of M. smithii in the obese gut (Zhang
et al., 2009; Schwiertz et al., 2010; Million et al., 2011). In addition,
the detection of Archaea in the vaginal flora of pregnant women
allowed us to hypothesize a possible mother-to-child transmission
(Dridi et al., 2011).
Planctomycetes
The phylum Planctomycetes, phylogenetically closely related to
Verrucomicrobia and Chlamydiae, is composed of environmen-
tal microorganisms characterized by a peptidoglycan-free cell wall
and cell compartmentalization (Fuerst and Sagulenko, 2011). The
culture is fastidious and requires the addition of appropriate
antibiotics (peptidoglycan synthesis inhibitors) and amphotericin
B to prevent contamination of the culture medium. Undetected by
conventional 16S rRNA PCR or standard culture techniques, this
phylum has been reported in black-and-white colobus monkey
stools (Yildirim et al., 2010) and, in one instance, in the human
gut microbiota, using metagenomics (De Filippo et al., 2010). In
our laboratory, preliminary results (unpublished data) confirmed
the presence of specific Planctomycetes DNA in human stools.
Several species of Planctomycetes and, more generally, of species
including the superphyla Verrucomicrobia, Planctomycetes, and
Chlamydiae, are undergoing genome sequencing. It is expected
that this sequencing will increase our knowledge of this specific
branch of the tree of bacterial life (Wagner and Horn, 2006).
The variability depending of the gut samples
“The gut microbiota is non-homogenous with a progressive
increase of bacterial concentration from the stomach (approxi-
mately 103 bacteria per gram to the colon (approximately 1011 bac-
teria per gram; O’Hara and Shanahan, 2006). Nevertheless, most
of studies explored stools samples reflecting mainly the colonic
composition. However, differences in compositions have been
reported between small intestine biopsies (most of Streptococ-
caceae belonging to Firmicutes phylum and Actinomycinaeae and
Corynebacteriaceae belonging to Actinobacteria phylum) whereas
colonic biopsies were enriched by Bacteroidetes phylum and Lach-
nospiraceae among the Firmicutes phylum (Frank et al., 2007).
Intestinal analysis of tiered samples will allow to exhaustively
describe the gut composition.”
COMPOSITION
The composition of the human gut ecosystem is influenced by
multiple and diverse factors, some physiological (age, origin, envi-
ronment) and others linked to external factors, such as dietary
habits, antibiotics, and probiotics (Figure 6).
AGE
In a pioneering study using microarrays to detect small rRNAs,
Palmer followed a cohort of newborns, including a pair of twins,
during the first year of life. It was shown that despite considerable
temporal variations and environmental influences, the compo-
sition of the intestinal ecosystem tended to be characteristic of
adulthood at the end of this period (Palmer et al., 2007). The pro-
portion of Bacteroides fragilis increased from 1 month to 1 year
(Vael et al., 2011). In a 2.5-year case study, Koenig analyzed
>300,000 16S rRNAs from 60 fecal samples from healthy children
and showed that infant gut variation is associated with life events.
The phylogenetic diversity of the microbiome increased gradually
over time with progressive temporal changes but, inversely, the
major phyla, genera, and species composition showed rough shifts
in abundance corresponding to modifications in diet or health
(Koenig et al., 2011).
Nevertheless, using microbiota array to analyze gut microbiota
composition in adolescent subjects, Agans et al. (2011) found
a statistically significantly higher abundance of Bifidobacterium
and Clostridium genera, contrary to current knowledge, suggest-
ing that the gut microbiome of adolescents is different from that
of adults. At the other extreme of life, using pyrosequencing of 16S
rRNA gene V4 region amplicons, the gut microbiota composition
of elderly subjects was distinct from that of younger adults, with
a greater temporal stability over a limited time, particularly in the
proportion of Bacteroides spp. (Claesson et al., 2011).
GEOGRAPHICAL PROVENANCE AND ENVIRONMENT
Discordant results have also been published regarding a geographic
signature of the gut microbiota depending on the technique used.
To investigate the hypothetical association between gut composi-
tion and cancer, early culture-dependent studies compared pop-
ulations at high-risk (western countries) and at low risk (Japan,
Uganda, India) and reported different compositions of microbiota
(Hill et al., 1971; Drasar et al., 1973; Finegold et al., 1974). The
high-risk population had a microbiota composed primarily of
Bacteroidetes, and there were specific differences, including pat-
terns of food consumption, between western countries and Asian
or African populations, although multiculturalism and population
exchanges have reduced these differences. Only a few large-scale
molecular studies have used stool samples collected from Asia or
Africa (De Filippo et al., 2010; Lee et al., 2011), where approx-
imately 75% of the population of the world lives; nevertheless,
the findings have suggested a possible signature of biogeography
(Lee et al., 2011). Indeed, most of the large-scale metagenomic or
pyrosequencing studies used stools collected from American or
European individuals (Ley et al., 2006b; Turnbaugh et al., 2006;
Claesson et al., 2011).
Lay, characterizing 91 European gut microbiota using FISH
combined with flow cytometry, did not observe a significant
grouping with regard to country of origin (France, Netherlands,
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Geographic
provenance
Asian vs American
European vs African
Southern vs Northern Europeans
Dietary Habits
Age
First month of life : Mostly Biﬁdobacteria
Diﬀerences in species level but
Contradictory results
1 month to 1 year of life : Increase Bacteroides fragilis
Adolescent : contradictory results
Vegetarians : 
Increase Bacteroidetes
Decrease Clostridia
Human gut
composi"on
Probio"cs
Adult: Stable: 
Firmicutes > Bacteroidetes
> Proteobacteria> Ac!nobacteria
Increase Lactobacillus spp. ?
Elderly: 
Increase Bacteroidetes
Decrease Biﬁdobacteria
Malnurished children : 
Increase Proteobacteria
Decrease bacterial load ?
Altera!on of composi!on ?
An"bio"cs
Malnutri"on
Decrease Bacteroidetes
FIGURE 6 |The influence of external factors determining the composition of the human gut microbiota.
Denmark, UK, and Germany; Lay et al., 2005). With the same tech-
nology, Mueller et al. (2006) found differences in Bifidobacteria
species between European individuals. Grzeskowiak et al. (2012),
using flow cytometry-FISH and qPCR, have shown that sev-
eral species (Bifidobacterium adolescentis, Staphylococcus aureus,
and Clostridium perfringens) were absent in Malawian children
but present in 6-month-old Finnish infants. Fallani comparing
infants living in northern or southern European countries by 16S
rDNA pyrosequencing, have found that geographical provenance
is important, with a higher proportion of Bifidobacteria in north-
ern infants and more Bacteroidetes and Lactobacilli in southern
European countries.
Finally, Arumugam studied 22 fecal metagenomes of individ-
uals from four different countries and identified three different
enterotype clusters, which were independent of geographic prove-
nance. The three different enterotypes were, respectively, richer in
Bacteroides, in Prevotella, and in Ruminococcus for the Enterotype
3. Arumugam suggested that each enterotype used a different route
to generate energy (Arumugam et al., 2011).
DIETARY HABITS
Dietary habits are thought to be a major factor contributing to
the diversity of the human digestive microbiota (Backhed et al.,
2005). Part of the geographic diversity of the gut microbiota
seems to be explained by differences in diet. For example, African
children from a rural area in Burkina Faso showed a specific
abundance of Prevotella and Xylanibacter, known to contain a
set of bacterial genes for cellulose and xylan hydrolysis, com-
pletely lacking in European children (De Filippo et al., 2010).
The authors hypothesized that the abundance of these genera
could be a consequence of the high intake of fiber, similar to
the diet of early human settlements at the time of the birth of
agriculture, maximizing the extraction of metabolic energy from
the polysaccharides of ingested plants (De Filippo et al., 2010).
A vegetarian diet affects the intestinal microbiota, specifically by
decreasing the amount and modifying the diversity of Clostrid-
ium cluster IV (Liszt et al., 2009). Based their studies on RFLP
analysis, Hayashi et al. (2002a) Hayashi found that the digestive
microbiota of vegetarians harbored Clostridium rRNA clusters
XIVa and XVIII. Recently, Walker et al. (2011) tested overweight
people successively with a control diet, a diet high in resistant
starch (RS) or non-starch polysaccharides (NSP) and a reduced
carbohydrate weight loss (WL) diet for 10 weeks by two different
methods: large-scale sequencing and quantitative PCR. No signifi-
cant effect was observed at the phylum level, but at finer taxonomic
level, Eubacterium rectale and Ruminococcus bromii showed signif-
icant and dramatic (fourfold) increased proportions in the RS diet,
whereas the proportion of Collinsella aerofaciens-related sequences
was decreased significantly on the WL diet (Walker et al., 2011).
In this study, reproducible changes were found only at the phy-
lotype level, whereas no differences were significant at a broader
taxonomic level (the phylum or family Ruminococcaceae level),
and the analysis suggested that the amplified 16S rRNA sequence
clustered more strongly by individuals than by diet. These changes
are entirely in agreement with studies using RNA-based stable iso-
tope probing, which showed that R. bromii was the first starch
degrader in the human gut (Kovatcheva-Datchary et al., 2009).
Wu analyzed stool samples from 98 individuals and found that
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enterotypes were strongly associated with long-term diets, espe-
cially for animal fat and protein (Bacteroides) vs. carbohydrate
(Prevotella). Changes in gut microbiota related to short-term diet
modifications occurred rapidly, were detectable within 3–4 days,
and were rapidly reversed (Walker et al., 2011; Wu et al., 2011).
Conversely, Wu et al. (2011) suggested that long-term dietary
interventions might allow the pervasive modulation of an individ-
ual’s enterotype to improve health. In animal models of obesity
induced by diet (DIO), Turnbaugh et al. (2008) showed that a
high-fat diet could significantly alter the intestinal flora of exper-
imental models with a bloom in a single uncultured clade within
the Mollicutes class of the Firmicutes. Hildebrandt et al. (2009)
suggested that a high-fat diet altered the intestinal flora regardless
of weight change. These authors observed a bloom of Clostridia
and Proteobacteria associated with the high-fat diet. The major
group of Proteobacteria that increased in abundance was the Delta-
Proteobacteria phylum, order Desulfovibrio. Finally, Monira et al.
(2011) have recently published a study comparing the gut flora
of malnourished children with that of well-nourished children in
Bangladesh and found a decrease in Bacteroidetes and an increase
in Proteobacteria phyla, including E. coli and Klebsiella spp.
OBESITY AND GNOTOBIOTIC MICE
Beginning in 2005, obesity has been associated with a specific
profile of bacterial gut microbiota, including a decrease in the
Bacteroidetes/Firmicutes ratio (Ley et al., 2005, 2006b; Turnbaugh
et al., 2006, 2009) and decreased bacterial diversity (Turnbaugh
et al., 2009). Since these pioneering studies, significant associa-
tions have been found between obesity and an increase in some
bacterial groups, including Lactobacillus, S. aureus, E. coli, and Fae-
calibacterium prausnitzii (Collado et al., 2008; Kalliomaki et al.,
2008; Armougom et al., 2009; Santacruz et al., 2009; Balamuru-
gan et al., 2010). In a recent review, we found no reproducible and
significant alteration linking obesity and gut microbiota at the phy-
lum level (Angelakis et al., 2012a). Conversely, meta-analysis at the
genus-level found decreased levels of bifidobacteria (Collado et al.,
2008; Kalliomaki et al., 2008; Santacruz et al., 2009; Balamurugan
et al., 2010; Schwiertz et al., 2010) and Methanobrevibacter spp.
(Armougom et al., 2009; Schwiertz et al., 2010; Million et al., 2011),
the leading known representative of Archaea in the human gut, in
overweight/obese people. To date, controversial studies show that
the connection between the microbiome and excess weight is com-
plex (Pennisi, 2011). We found a difference at the species level, with
L. reuteri enriched in obese gut microbiota, whereas L. plantarum
was increased in lean individuals (Million et al., 2011). At the
gene level, obesity has been associated with an altered representa-
tion of bacterial genes and metabolic pathways. Turnbaugh et al.
(2009) showed that diversity of organismal assemblages yields a
core microbiome at a functional level and that deviations from this
core are associated with different physiological states (obese com-
pared with lean), with obese gut microbiota having an increased
capacity for energy harvest.
As a theoretical basis for the causal link between alterations in
the gut microbiota and obesity, several mechanisms have been
suggested. First, the gut microbiota may interact with weight
regulation by hydrolyzing indigestible polysaccharides to easily
absorbable monosaccharides and by activating lipoprotein lipase.
Consequently, glucose is rapidly absorbed, producing substantial
elevations in serum glucose and insulin, both factors that trigger
lipogenesis. In addition, fatty acids are stored excessively, with de
novo synthesis of triglycerides derived from the liver. Together,
these phenomena cause weight gain (Backhed et al., 2007). Using
Fasting-Induced Adipocyte Factor (Fiaf) knockout mice, Backhed
et al. (2007) showed that gut microbiota suppressed intestinal Fiaf,
consequently increasing the storage of calories.
Second, the composition of gut microbiota has been shown
to selectively suppress angiopoietin-like protein 4/fasting-induced
adipose factor in the intestinal epithelium. This molecule is a cir-
culating lipoprotein lipase inhibitor and a regulator of peripheral
lipid and glucose metabolism (Backhed et al., 2004). Backhed et al.
(2004) showed that when the microbiota of normal mice were
transplanted into germ-free mice, after 2 weeks, body fat increased
by 60% without increased food consumption, modifications of
energy expenditure, or relative insulin resistance, and there was a
2.3-fold higher production of triglycerides in the liver, suggesting
that the gut operates in host energy homeostasis and adiposity.
Third, it has been suggested that bacterial isolates of gut micro-
biota may have pro- or anti-inflammatory properties, impact-
ing weight. Obesity has been associated with a low-grade sys-
temic inflammation corresponding to higher plasma endotoxin
lipopolysaccharide (LPS) concentrations, defined as metabolic
endotoxemia (Bastard et al., 2006; Hotamisligil, 2006; Sbarbati
et al., 2006; Fogarty et al., 2008). Cani et al. (2008) showed that
antibiotics can lower LPS levels in mice fed a high-fat diet and
in ob/ob mice and, consequently, can reduce glucose intolerance,
body weight gain, and fat mass. Conversely, some Bifidobacterium
and Lactobacillus species have been reported to deconjugate bile
acids, which may decrease fat absorption (Shimada et al., 1969).
ANTIBIOTICS AND PROBIOTICS
Antibiotics and total bacterial count
According to the literature, oral or intravenous antibiotics tend
to decrease the bacterial load in the digestive tracts of infants
(Palmer et al., 2007) and elderly patients (Bartosch et al., 2004).
However, other studies reported that only the microbiota compo-
sition is altered, and the total biomass is not modified by antibiotics
(Sekirov et al., 2008). In contrast to amoxicillin and metronidazole
or cefoperazone, Robinson noted that the alterations in commu-
nity structure associated with vancomycin specifically occurred
without a significant decrease in the overall bacterial biomass
(Robinson and Young, 2010).
Structural disruption
Antibiotic administration has a reproducible effect on the com-
munity structure of the indigenous gastrointestinal microbiota
in mice (Robinson and Young, 2010). A very recent study found
that the administration of a commercial growth-promoting antibi-
otic combination (ASP250: chlortetracycline-sulfamethazine and
penicillin) entailed a reproducible bloom in proteobacteria (1–
11%) in swine gut microbiota (Looft et al., 2012). This shift was
driven by an increase in E. coli populations. In humans, analy-
sis of the fecal microbial populations of infants after antibiotic
therapy showed a major alteration as measured by SSU rDNA
microarray analysis (Palmer et al., 2007) or culture-based methods
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(Savino et al., 2011). In adults, the same dramatic shift has been
reported, depending on the antibiotic. Clindamycin (Donskey
et al., 2003; Jernberg et al., 2005a) has the strongest effect com-
pared to oral cephalosporin, which is responsible for minor or no
changes (Swedish Study Group, 1991a,b). Of note, the extremely
moderate effect of cephalosporin on gut microbiota (Donskey
et al., 2003) has been linked with the low activity of this mol-
ecule on intestinal anaerobes. Moreover, the fecal elimination of
carbapenems is very limited, explaining why changes in the intesti-
nal microflora are only moderate, whereas these agents have the
broadest spectra of the beta-lactam antibacterial agents (Sullivan
et al., 2001). The characterization of gut microbiota alteration
by metagenomic analysis of the v3–v6 region has been stud-
ied in three patients on ciprofloxacin (Dethlefsen et al., 2008).
Ciprofloxacin decreased to one-third the abundance of taxa [num-
ber of ref Operational taxonomic units (OTU)], their diversity
and distribution. However, comparing gut microbiota alterations
by DGGE analysis, the rate of similarity with the pre-treatment
profile was 73% with ciprofloxacin but only 11–18% with clin-
damycin (Donskey et al., 2003). In addition, ciprofloxacin has been
reported to have little or no impact on anaerobic intestinal micro-
biota (Nord, 1995; Edlund and Nord, 1999b). Glycopeptides, used
widely in agriculture as growth promoters, are associated with
natural resistance of most of the lactobacilli and have no effect
on gram-negative bacteria, including Enterobacteria (Barna and
Williams, 1984). Analyzing vancomycin-associated gut microbiota
alterations in mice by cloning sequencing, Robinson found that
vancomycin increased members of the Proteobacteria and Tener-
icutes phyla and the Lactobacillaceae family, whereas members
of the Lachnospiraceae family decreased (Robinson and Young,
2010). Using a continuous-culture colonic model system, Macca-
ferri et al. (2010) demonstrated that rifaximin, reported to induce
clinical remission of active Crohn’s disease while not altering
the overall structure of the human colonic microbiota, increased
Bifidobacterium, Atopobium, and F. prausnitzii and led to a vari-
ation of metabolic profiles associated with potential beneficial
effects on the host. The effects of tetracycline on gut micro-
biota in humans are of particular interest because this antibiotic
is commonly used in poultry production as a growth promoter,
suggesting dramatic changes in intestinal microbial populations.
One notable effect of tetracycline is a decrease in bifidobac-
teria (Nord et al., 2006; Saarela et al., 2007). Overall, specific
gut microbiota changes are associated with specific antibiotics
(Table 1).
The effects of three growth-promoting antibiotics (avilamycin,
zinc bacitracin, and flavomycin) on broiler gut microbial com-
munity colonization and bird performance were investigated
(Torok et al., 2011). OTU linked to changes in gut microbiota in
birds on antimicrobial-supplemented diets were characterized and
identified. Lachnospiraceae, L. johnsonii, Ruminococcaceae, and
Oxalobacteraceae genera were less prevalent in the guts of chicks
fed antimicrobial-supplemented diets. L. crispatus, L. reuteri, Sub-
doligranulum, and Enterobacteriaceae were more prevalent in the
guts of chicks raised on the antimicrobial diet (Torok et al., 2011).
These results suggest that antibiotic effects on gut microbiota
may be relevant at the species level because different Lactobacillus
species-related OTUs showed paradoxical changes.
The reversibility of structural gut microbiota modification
The recovery of the gut community toward baseline after short-
term antibiotic therapy has been reported in animal models
(Robinson and Young, 2010), but pervasive disturbance to the
community has been observed several weeks after withdrawal of
certain antibiotics, including cefoperazone (Robinson and Young,
2010) and quinolones (Dethlefsen et al., 2008). Changing the
intestinal microbiota of termites with antibiotics offers a privileged
experimental model and has shown that prolonged antibiotic
treatment with rifampicin has an irreversible effect not only
on microbial diversity but also on longevity, fecundity and the
weight (weight gain compared to controls) of two termite species,
Zootermopsis angusticollis and Reticulitermes flavipes.
Probiotics
Probiotics were initially used in agriculture to prevent diarrhea in
poultry because they reduce intestinal colonization by Salmonella
spp. and C. perfringens (Angelakis and Raoult, 2010), but the use
of probiotics such as Lactobacillus spp. can led to a rapid weight
increase in chickens (Angelakis and Raoult, 2010). L. acidophilus,
L. plantarum, L. casei, L. fermentum, and L. reuteri are the most
commonly used Lactobacillus species in agriculture (Anadon et al.,
2006). The inoculation of L. ingluviei in mice is responsible for
gut flora alterations associated with an increase in weight gain and
liver enlargement (Angelakis et al., 2012b). In parallel, probiotics
are increasingly used in human foods, notably in the milk indus-
try (Raoult, 2008). Although the mechanisms are not yet known,
many studies suggest that probiotics function through direct or
indirect impacts on colonizing microbiota of the gut (Sanders,
2011). Million et al. (2011) recently found that different Lacto-
bacillus species may have a paradoxical effect, with higher levels
of L. reuteri and lower levels of L. plantarum and L. paracasei in
obese gut microbiota. A recent systematic meta-analysis reported
that the administration of L. acidophilus is responsible of weight
gain in human and animals and that the use of L. fermentum and L.
ingluviei resulted of weight gain in animals (Million et al., 2012).
Thuny et al. (2010) observed a weight gain in patients treated
with vancomycin and hypothesized that the gain was induced by
the growth-promoting effect of Lactobacillus spp., as these species
are resistant to glycopeptides. In contrast, symbiotics (the combi-
nation of prebiotics and probiotics) have been proposed for the
management of malnutrition, with promising results on mortality
(Kerac et al., 2009). After gavage of gnotobiotic mice with a combi-
nation of bacteria, including B. animalis subsp. lactis, L. delbrueckii
subsp. bulgaricus,Lactococcus lactis subsp. cremoris, and Streptococ-
cus thermophilus, only anecdotal changes were noted in microbiota
composition, whereas significant changes were observed in the
expression of microbiome-encoded enzymes involved in meta-
bolic pathways, notably, carbohydrate metabolism (McNulty et al.,
2011). However, these suggestions of a relationship between probi-
otics and obesity remain controversial (Delzenne and Reid, 2009).
In addition, the reports of the anti-diabetic and anti-inflammatory
effects of Lactobacilli should be considered cautiously because the
translation of findings based on animal models to humans is haz-
ardous (Kootte et al., 2012). Finally, all these results should be
interpreted with caution in view of the substantial funding of
obesity research by the food industry, creating conflicts of interest.
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Table 1 | Modifications of gut flora linked to antibiotics.
Antibiotic Method References
PENICILLINS
Ampicillin
Decrease in enterococci Cultivation Black et al. (1991)
Decrease in streptococci Cultivation Black et al. (1991)
Decrease in E. coli strains Cultivation Black et al. (1991)
Slight decrease in anaerobic Gram-positive bacteria Cultivation Black et al. (1991)
Amoxicillin
Increase in aerobic Gram-negative rods, such as
enterobacteria, other than E. coli (Klebsiella, Enterobacter )
Cultivation Brismar et al. (1993), Floor et al. (1994), Stark et al. (1996)
Increase in anaerobic Gram-positive rods Cultivation Swedish Study Group (1991b)
Increase in Bacteroides Cultivation Swedish Study Group (1991b)
Decrease in streptococci and Staphylococci Cultivation Brismar et al. (1993)
Decrease in anaerobic Gram-positive cocci, such as
eubacteria
Cultivation Brismar et al. (1993), Stark et al. (1996)
Amoxicillin/clavulanic acid
Increase in enterococci and E. coli Cultivation Lode et al. (2001)
Decrease in lactobacilli, clostridia, bifidobacteria Cultivation Lode et al. (2001)
Disappearance of Clostridium cluster XIVa
(cloning/sequencing)
Cloning/sequencing Young and Schmidt (2004)
Decrease in Faecalibacterium spp. Cloning/sequencing Young and Schmidt (2004)
Piperacillin/tazobactam*
Decrease in enterobacteria Cultivation Nord et al. (1993)
Decrease in bifidobacteria, eubacteria, lactobacilli Cultivation Nord et al. (1993)
Decrease in anaerobic Gram-positive cocci like clostridia Cultivation Nord et al. (1993)
CEPHALOSPORINS
Cefepime
Decrease in E. coli and bifidobacteria Cultivation Bacher et al. (1992)
Increase in clostridia and Bacteroides Cultivation Bacher et al. (1992)
Ceftriaxone
Decrease in the total numbers of anaerobes Cultivation Welling et al. (1991)
Dramatic decrease in clostridia, lactobacilli, bifidobacteria Cultivation Vogel et al. (2001)
Dramatic decrease in Gram-negative rods (enterobacteria) Cultivation Cavallaro et al. (1992), Vogel et al. (2001), Welling et al. (1991)
Increase in enterococci Cultivation Vogel et al. (2001), Welling et al. (1991)
Carbapenems
Meropenem
Decrease in enterobacteria and streptococci Cultivation Bergan et al. (1991)
Increase in enterococci Cultivation Bergan et al. (1991)
Decrease in clostridia, Gram-negative cocci, and bacteroides Cultivation Bergan et al. (1991)
FLUOROQUINOLONES
Ciprofloxacin
Dramatic decrease in enterobacteria Cultivation Bergan et al. (1986), Borzio et al. (1997), Brismar et al.
(1990), Brumfitt et al. (1984), Enzensberger et al. (1985),
Esposito et al. (1987), Holt et al. (1986), Krueger et al.
(1997), Ljungberg et al. (1990), Rozenberg-Arska et al.
(1985), Van Saene et al. (1986), Wistrom et al. (1992)
Decrease in aerobic Gram-positive cocci Cultivation Bergan et al. (1986), Brismar et al. (1990), Brumfitt et al.
(1984), Ljungberg et al. (1990), Van Saene et al. (1986)
Decrease in streptococci Cultivation Brismar et al. (1990), Brumfitt et al. (1984), Ljungberg et al.
(1990)
Decrease in enterococci Cultivation Bergan et al. (1986), Brismar et al. (1990), Ljungberg et al.
(1990), Van Saene et al. (1986)
(Continued)
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Table 1 | Continued
Antibiotic Method References
Increase in enterococci Cultivation Borzio et al. (1997)
Decrease in anaerobic bacteria Cultivation Bergan et al. (1986), Brismar et al. (1990), Rozenberg-Arska
et al. (1985)
Suppression of Bacteroides putredinis, Ruminococcus
torques
DGGE Donskey et al. (2003)
Norfloxacin
Dramatic decrease in enterobacteria Cultivation de Vries-Hospers et al. (1985), Edlund et al. (1987), Leigh
et al. (1985), Pecquet et al. (1986)
Decrease in aerobic Gram-positive cocci Cultivation de Vries-Hospers et al. (1985), Pecquet et al. (1986)
Decrease in streptococci Cultivation Pecquet et al. (1986)
Decrease in enterococci Cultivation de Vries-Hospers et al. (1985)
Ofloxacin
Dramatic decrease in enterobacteria Cultivation Edlund et al. (1988), Edlund et al. (1997b), Pecquet et al.
(1987)
Decrease in aerobic Gram-positive cocci Cultivation Edlund et al. (1988), Edlund et al. (1997b), Pecquet et al.
(1987)
Decrease in enterococci Cultivation Edlund et al. (1988), Pecquet et al. (1987)
Decrease in lactobacilli, bifidobacteria, eubacteria Cultivation Edlund et al. (1988)
Decrease in anaerobic bacteria Cultivation Edlund et al. (1988)
Decrease in Veillonella and Bacteroides spp. Cultivation
Levofloxacin, Gatifloxacin,Trovafloxacin, Moxifloxacin
Dramatic decrease in enterobacteria Cultivation Edlund et al. (1997b), Edlund and Nord (1999a), van Nispen
et al. (1998)
Strong decrease in aerobic Gram-positive cocci Cultivation Edlund et al. (1997b), Edlund and Nord (1999a), van Nispen
et al. (1998)
Levofloxacin, gatifloxacin: decrease in clostridia Cultivation Edlund et al. (1997b), Edlund and Nord (1999a)
Gatifloxacin: decrease in fusobacteria Cultivation Edlund and Nord (1999a)
GLYCOPEPTIDS
Oral vancomycin
Decrease in enterococci Cultivation Edlund et al. (1997a), Lund et al. (2000)
Decrease in staphylococci Cultivation Van der Auwera et al. (1996)
Overgrowth of lactobacilli (and pediococci) Cultivation Edlund et al. (1997a), Lund et al. (2000), Van der Auwera
et al. (1996)
Strong suppression or elimination of bacteroides Cultivation Edlund et al. (1997a), Lund et al. (2000)
Decrease in clostridia and bifidobacteria Cultivation Lund et al. (2000)
Oral teicoplanin
Increase in Gram-negative aerobic rods and total numbers
of aerobes
Cultivation Van der Auwera et al. (1996)
Increase in lactobacilli and pediococci Cultivation Van der Auwera et al. (1996)
LINEZOLID
Reduction of enterococci Cultivation Lode et al. (2001)
Reduction of bifidobacteria, lactobacilli, clostridia, and
bacteroides
Cultivation Lode et al. (2001)
Increase in Klebsiella Cultivation Lode et al. (2001)
TETRACYCLINES
Doxycycline
Decrease in bifidobacteria Cultivation Saarela et al. (2007)
Tigecycline
Decrease in enterococci Cultivation Nord et al. (2006)
Decrease in E. coli Cultivation Nord et al. (2006)
Increase of other enterobacteria (Klebsiella and
Enterobacter spp.)
Cultivation Nord et al. (2006)
(Continued)
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Antibiotic Method References
Marked reduction of lactobacilli and bifidobacteria Cultivation Nord et al. (2006)
Increase in yeasts Cultivation Nord et al. (2006)
MACROLIDES, LINCOSAMIDES, SYNERGISTINS
Erythromycin
Dramatic decrease in streptococci and enterobacteria Cultivation Brismar et al. (1991)
Decrease in clostridia, lactobacilli, bifidobacteria, and
bacteroides
Cultivation Brismar et al. (1991)
Clarithromycin
Reduction of enterobacteria, E. coli, and streptococci Cultivation Brismar et al. (1991), Edlund et al. (2000b)
Dramatic decrease in clostridia, and bacteroides Cultivation Brismar et al. (1991)
Reduction of lactobacilli and bifidobacteria Cultivation Brismar et al. (1991), Edlund et al. (2000b)
Telithromycin
Decrease in E. coli but overgrowth of non-E. coli
enterobacteria
Cultivation Edlund et al. (2000a)
Reduction of lactobacilli and bifidobacteria Cultivation Edlund et al. (2000a)
Clindamycin
Increase in enterobacteria T-RFLP Jernberg et al. (2005b)
Decrease in total anaerobic bacteria Cultivation Nord et al. (1997)
Decrease in lactobacilli and Bacteroides Cultivation Nord et al. (1997), Sullivan et al. (2003)
Decrease in clostridia Cultivation Nord et al. (1997)
Disappearance of bifidobacteria Cultivation Jernberg et al. (2005b), Nord et al. (1997)
Dramatic decrease in Bifidobacterium, Clostridium
(particularly C. coccoides subgroup as Eubacterium) and
Bacteroides
T-RFLP Jernberg et al. (2005b)
Suppression of B. vulgatus, B. acidofasciens, F. prausnitzii,
C. indolis, and C. leptum cluster
DGGE Donskey et al. (2003)
No change in B. thetaiotaomicron and B. uniformis DGGE Donskey et al. (2003)
Streptogramins: Quinupristin/dalfopristin
Decrease in anaerobic Gram-negative bacteria Cultivation Scanvic-Hameg et al. (2002)
Increase in enterococci and enterobacteria Cultivation Scanvic-Hameg et al. (2002)
OTHERS
Cotrimoxazole
Suppression of Enterobacteriaceae Cultivation Mavromanolakis et al. (1997)
Metronidazole
No significant change but not enough data available Cultivation Sullivan et al. (2001)
Nitrofurantoin
No impact on intestinal microflora Cultivation Mavromanolakis et al. (1997)
REDUCTIONIST APPROACH AND BIASES
In their attempts to reduce ignorance and in contrast to the
holistic approach based on the combination of conventional tech-
niques and technology-driven methods, which enable researchers
to study and make sense of a complex ecosystem, diverse stud-
ies based on experimental models have induced reductionism
in the understanding of human microbiota and have generated
contradictory results (Raoult, 2010; Fang and Casadevall, 2011).
HYPOTHESIS-DRIVEN RESEARCH VERSUS HOLISTIC-DRIVEN
RESEARCH
Because it has been suggested that gut microbiota play a role in
health and disease, it has been attractive to find a stable model
to help scientists to understand host-gut microbiota mutualism,
but this relationship is very complex and involves control diets,
genetics, and environmental conditions. The first germ-free model
was used by Pasteur in 1885. Since that time, various models have
been used to study gut microbiota, including germ-free neona-
tal pigs (Meurens et al., 2007), zebrafish (Rawls et al., 2004), and
gnotobiotic mice, which is the most effective tool (Backhed et al.,
2007; Goodman et al., 2011).
Conversely, based on observations and not supported by any
preconceived hypothesis, several findings by different research
teams have shown a significant reduction in Bacteroidetes propor-
tions in obese patients (Armougom et al., 2009; Turnbaugh et al.,
2009; Million et al., 2011). Comparing the composition of the
gut microbiota between young adult female monozygotic or dizy-
gotic twins who are obese or lean and their mothers, Turnbaugh
found that obesity was associated with reduced bacterial diversity
and, notably, a reduced proportion of Bacteroidetes. Moreover, the
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genes over-represented within obese individuals exclusively belong
to the Firmicutes phylum (Turnbaugh et al., 2009). Nevertheless,
previous investigations based on genomic data and experimental
models have shown that co-colonization of B. thetaiotaomicron
and M. smithii in the digestive tract of xenobiotic mice was
responsible for significant weight gain, with discordance between
sequence analysis results and the initial hypothesis (Xu et al., 2003;
Samuel and Gordon, 2006).
CONFLICTS OF INTEREST
Finally, to exhaustively review the topic of human gut microbiota
composition and mutualism with the host, it would be morally
objectionable not to address the central influence of funding
sources and transparency disclosures (Million and Raoult, 2012).
A transparency declaration of conflict of interest is important
for publication in the medical literature. Lundh et al. (2010), based
on the articles published in six of the most prestigious medical
journals, showed that the publication of studies financed by indus-
tries was associated with an increase in the impact factor of the
journal. Regarding the economic aspect and the payment of physi-
cians by five manufacturers of hip and knee prostheses, a recent
study confirmed that only approximately 80% of direct payments
and 50% of indirect payments to physicians have been disclosed
(Okike et al., 2009). Some authors even consider that publications
in medical journals are a marketing tool for the pharmaceutical
industry (Smith, 2005). In the beverage and food industry, Levine
studied the financial relationships between industry and authors
who have published research on alimentary substitutes. Classifying
these publications as neutral, critical, or supportive toward the ali-
mentary substitutes, the authors suggested a significant association
between the authors who support the efficiency of the substitute
and the authors with financial relationships with the industrial
company (Levine et al., 2003).
Finally, Thomas et al. (2008) has recently shown that of
63 randomized trials published regarding nutrition and obesity,
67% were supported by the food industry. Moreover, the results
of industry-supported trials were significantly associated with a
higher quality of reporting score associated with long-term WL.
Moreover, compounding this problem, some scientists do not
declare their conflicts of interest. Based on these data, and the
considerable financial involvement associated with human gut
microbiota research, notably in obesity, we regret that there is not
more public funding (Smith, 2005), and that conflict of interest
with food industry are not actively required as for pharmaceutical
industry.
CONCLUDING REMARKS
Factors affecting the composition of the gut microbiota and the
relationship with the hosts are of considerable complexity. Both
physiological and external factors are often unstable over time,
influencing the gut microbiota. Despite the contribution of recent
technologies, the repertoire of this ecosystem remains incomplete.
As a striking example, despite the dramatic increase in the num-
ber of publications regarding gut microbiota, simplistic anomalies
persist, such as the discordance among microscopic observation,
pyrosequencing, and culture results. We regret that fewer studies
are based on observation and description in opposition to studies
performed to confirm a hypothesis. Indeed, it is paradoxical to
design experiments and models to confirm a hypothesis because
the ecosystem is only partially described. Finally, the central prob-
lem of funding sources and transparency declarations lead us to
hope that public funding will develop food-industry-independent
research to increase confidence in the results.
In the future, we think that culturomics followed by the high-
throughput genome sequencing and its applications as the explo-
ration of host-pathogen interactions will allows to capture the rela-
tionships in the gut microbiota. In addition, technology advances
in pyrosequencing with higher reads fragment analysis, may facil-
itate the analysis to low taxonomic level (genera, species) reducing
consequently the depth bias.
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